Podcasts about cytoreason

Shai Shen-Orr, the Co-Founder and Chief Scientist of CytoReason, is developing computational disease models powered by AI to improve the probability of success in phase 2 clinical trials. Their goal is to more precisely develop drugs using AI to analyze large amounts of biological and clinical data and overcome the challenges of the complexity and uncertainty in medical information. Working with large pharmaceutical companies, CytoReason is supporting companies in their drug development efforts and helping them choose the right drug target and patient populations to study.   Shai explains, "There are many challenges. I would say that CytoReason right now isn't tackling images. And there are certainly companies in the field that have been doing this. We've been focused more on the molecular side of the data, the genes, the proteins, the cells, the genetics. But the challenge is that when you work in this field and try to do AI in biology, it's very difficult for us to know the ground truth. We don't know when we're wrong or when we're right." "We strive to support as many diseases as we can. Where we've placed the focus now has been immunology and oncology and, particularly, immuno-oncology. We kind of grew up as a company that really can specialize in the immune system. While the immune system plays a role in almost every disease, there are particular diseases, autoimmune diseases, and oncology, where it plays a very large role."  "So now when we develop drugs, drug developers are thinking very much across the board, they're thinking about the mechanisms of the disease. They keep asking themselves where are there similar mechanisms that are triggering diseases that may be ultimately, from a physiological perspective, from a disease perspective, the patients may look very different, they may even have a different disease. Yet, from the drug perspective, what the drug is hitting, the mechanisms are similar. And so we need to support that. We need to support the ability of drug developers to think across the board. That also plays into the role of which models we prioritize." #CytoReason #PharmaAI #AI #DrugDiscovery #DrugDevelopment #ClinicalTrials cytoreason.com Download the transcript here

Shai Shen-Orr, the Co-Founder and Chief Scientist of CytoReason, is developing computational disease models powered by AI to improve the probability of success in phase 2 clinical trials. Their goal is to more precisely develop drugs using AI to analyze large amounts of biological and clinical data and overcome the challenges of the complexity and uncertainty in medical information. Working with large pharmaceutical companies, CytoReason is supporting companies in their drug development efforts and helping them choose the right drug target and patient populations to study.   Shai explains, "There are many challenges. I would say that CytoReason right now isn't tackling images. And there are certainly companies in the field that have been doing this. We've been focused more on the molecular side of the data, the genes, the proteins, the cells, the genetics. But the challenge is that when you work in this field and try to do AI in biology, it's very difficult for us to know the ground truth. We don't know when we're wrong or when we're right." "We strive to support as many diseases as we can. Where we've placed the focus now has been immunology and oncology and, particularly, immuno-oncology. We kind of grew up as a company that really can specialize in the immune system. While the immune system plays a role in almost every disease, there are particular diseases, autoimmune diseases, and oncology, where it plays a very large role."  "So now when we develop drugs, drug developers are thinking very much across the board, they're thinking about the mechanisms of the disease. They keep asking themselves where are there similar mechanisms that are triggering diseases that may be ultimately, from a physiological perspective, from a disease perspective, the patients may look very different, they may even have a different disease. Yet, from the drug perspective, what the drug is hitting, the mechanisms are similar. And so we need to support that. We need to support the ability of drug developers to think across the board. That also plays into the role of which models we prioritize." #CytoReason #PharmaAI #AI #DrugDiscovery #DrugDevelopment #ClinicalTrials cytoreason.com Listen to the podcast here

Tom Bumol's career spans major roles at Eli Lilly, the Allen Institute, and beyond. He is also a distinguished member of CytoReason's Science Advisory Board.In this episode, Tom shares insights into drug development's successes, failures, and future direction, including:Lessons from lupus - the story of a failed lupus trial that revealed the critical importance of understanding disease heterogeneity and inspired new approaches in immunology.From trial and error to predictability - how AI and systems biology can transform drug development by embracing human complexity.Combination therapies and beyond - designing drugs with precision to improve patient outcomes and broaden therapeutic reach.All this and much more in a captivating discussion with our Chief Scientist Shai Shen-Orr. Enjoy!

On this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.  David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason's models differ from existing approaches, and the benefits they offer in accelerating drug development. They also delve into the evolving role of AI in drug discovery, the transformative potential it holds, and the critical challenges the industry will face as the field scales.    Reflecting on the importance of diverse thinking in this fast-evolving space, David notes, "Diversity of opinions is critical to making things work. You need diverse perspectives to distill the truth before it's delivered to the customer, who is highly educated and smart. Without tough questions being asked openly, things can fall apart quickly."  David also offers three key pieces of advice for entrepreneurs looking to enter the intersection of AI and life sciences today.Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 1:14 To start, nothing in your background said AI or disease biology, how did you decide to work in this space and what motivated you to co-found CytoReason? 5:50 Why hadn't anyone done this before with molecular data? And how was it different from what was being done? 6:54 Did the vision for CytoReason stay the same or evolve? 7:30 The big question, where do you get the data and is it proprietary? 10:28 What do CytoReason's models do? What is the benefit and how does this help drug development? 13:50 How are you thinking about building your business out to tackle the industry? 22:00 How do you foresee the role of AI evolving in drug discovery and development, and what challenges do you anticipate as the field grows? 28:55 What advice would you give to entrepreneurs looking to enter the intersection of AI and life sciences today?

This episode was recorded in the beautiful Island of Crete, at CytoReason's employee conference, the CytoSummit.CytoReason's Co-founder Shai Shen-Orr hosts AION Labs CTO Yair Benita. Yair is a computational biologist who spent more than 20 years studying biology through omics and clinical data in an effort to piece together mechanisms of human disease. He's been leading computational teams in drug discovery at CytoReason, Compugen, and Merck. In this candid conversation with Shai, Yair reflects on the highs and lows of his professional journey over the past two decades, as well as the broader industry landscape.Key questions discussed include:What major shift did Keytruda's development introduce to the industry?How did pharma's 'Kodak moment' come about?What needs to happen in pharma R&D so data is no longer JUST supporting decisions, but actually driving them?And plenty of other industry gems. Enjoy!

Jeremy Skillington CEO of Poolbeg Pharma: "During H1 2023, we made significant progress in advancing our pipeline, bolstered by the strong clinical trial data for POLB 001 and breakthroughs in our AI-led drug discovery programmes. We are well positioned for ongoing development and future growth with a strong focus on our business development activities." Interim Results Highlights and Business Update ·    Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) ·    Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to be an effective treatment for severe influenza and potentially other acute inflammatory conditions ·    Strategic expansion of POLB 001 into oncology, including as a potential treatment option for Cytokine Release Syndrome (CRS), a side-effect associated with up to 95% of CAR T cell therapies ·    Further to discussions with prospective partners interested in this area, the Company is actively exploring a potential new indication for POLB 001 in oncology beyond CAR T   ·    The Company's artificial intelligence (AI) programme with CytoReason provided unparalleled insights into influenza infection and successfully identified a number of novel and valuable drug targets ·    The lab-based validation of the Respiratory Syncytial Virus (RSV) drug targets and treatments identified from the Company's AI-led programme is progressing and expected to complete in H2 2023 ·    The Poolbeg-led Oral Vaccine consortium (EncOVac), which was awarded €2.3 million in grant funding, progressed to the next phase of development, marked by the commencement of the encapsulation validation process ·    Continued progress on the Oral GLP-1 agonist proof-of-technology clinical trial preparation. As a result of adopting recommendations from a number of Key Opinion Leaders (KOLs), the clinical trial design has been refined and the trial is expected to commence in H1 2024 ·    Industry veteran, Professor Brendan Buckley, appointed as Non-Executive Director in May 2023 To read the full RNS click here

(Watch the video interview HERE) Jeremy Skillington, CEO of Poolbeg Pharma (POLB ), talks us through the results of its successful collaboration with leading AI specialist CytoReason, making at a pioneer in AI-enabled drug discovery. 0:28 Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg's POLB001 treatment. 2:07 How the approach to analyse human challenge data for influenza with AI is the first of its kind. 3:28 Next steps after the successful conclusion of the collaboration, moving towards partnership. 4:54 Why Poolbeg is at the forefront of AI-enabled drug discovery

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."

CytoReason is supporting some of the largest pharma companies and research institutes with their boldest attempts to improve people lives through improved clinical design and speeding the discovery of new life-saving drugs. Using the knowledge the world has accumulated to intelligently augment clients' data and to identify patterns within it and generate a system-level understanding of immunity. These patterns then become powerful tools for explaining, predicting and optimizing outcomes proving guidance in both drug discovery and clinical trials. I spoke with David from his office in TelAviv and here is some of what we touched on: - What it means to be the first cell-centered computational model for human disease. - How CytoReason's massive database and AI-led platform supports the pharma and the biotech space to make decisions on what drug to give to what patients. - It's not one company, it's not one person, it's not the brilliance of one researcher or one invention but rather a long, long, long chain of people, different people, different companies, different research institutions, different governments all contributing to bringing therapy to a patient somewhere in the world. - Five of the world's top 10 pharma companies use CytoReason technology in order to manage their research and development. - The why behind his personal drive to improve patient outcomes in healthcare. - The early stages of getting the business off the ground and bootstrapping the company until they knew the exact value they could bring to the market and then scaling to 150 team members globally. David Harel, co-founder and CEO of CytoReason, is a well-rounded business leader with proven strategic thinking and demonstrated execution in healthcare, technology and finance. He spent the first part of his career in private equity, focusing on strategy and financing of growth companies in industrial and healthcare IT markets. Prior to CytoReason, David served as the CEO of Virtual OfficeWare Healthcare Solutions. He is an expert at evaluating business models, creating targeted go-to-market plans and focusing on the right opportunities. David has excellent negotiation skills with the ability to close large contracts. David also has direct experience in P&L management, M&A, market evaluation, sales planning and financial analysis. Connect with David: Website: https://www.cytoreason.com/ Connect with Allison: LinkedIn: https://www.linkedin.com/in/allisonsummerschicago/ Website: DisruptiveCEONation.com Twitter: @DisruptiveCEO    #futurist #CEO #startup #startupstory #founder #founderstory #business #businesspodcast #podcast               Learn more about your ad choices. Visit megaphone.fm/adchoices

Our first episode features world renowned epidemiologist, Prof. Ran Balicer, Chief Innovation Officer at Clalit Health Services, Israel's largest healthcare organization. We talked about the mining of real-world data and how it guides healthcare policy. The impact on Covid is pretty mind-boggling!

This is a podcast about the future of pharma. From novel targets to novel biomarkers. From disease models to population models. From clinical trials to synthetic trials. In each episode, our host Prof. Shai Shen-Orr talks to world-leading scientists and healthcare executives about the future of pharma.

David Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development. David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But people who have been involved in the molecular data space for a while know that the integration of multiple data types and multiple data sets is very difficult, and it needs to be done in a certain context. The context in which we are incorporating the data is allowing the users to run those synthetic trials on their own or using our teams." "One of the features that we have is the ability to run synthetic basket trials. So, take one drug, assuming the drug you want to evaluate, and run it across multiple indications in these dozens of indications. To conduct that with human subjects is prohibitive for cost and ethical reasons. And the same way, when we are conducting synthetic umbrella trials, where we're taking a specific patient population, and we are evaluating the efficacy of many different compounds in a specific patient population. Again, this would be very difficult to conduct in a clinical setting with human subjects. These are things that synthetic in silico trials allow you to do that clinical endeavors would not." @CytoReason #DiseaseModels #ComputationalDiseaseModels #SyntheticClinicalTrials #ClinicalTrials #ComputationalBiology #DrugDevelopment #DrugDiscovery #AI #RareDiseases CytoReason.com Download the transcript here

David Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development. David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But people who have been involved in the molecular data space for a while know that the integration of multiple data types and multiple data sets is very difficult, and it needs to be done in a certain context. The context in which we are incorporating the data is allowing the users to run those synthetic trials on their own or using our teams." "One of the features that we have is the ability to run synthetic basket trials. So, take one drug, assuming the drug you want to evaluate, and run it across multiple indications in these dozens of indications. To conduct that with human subjects is prohibitive for cost and ethical reasons. And the same way, when we are conducting synthetic umbrella trials, where we're taking a specific patient population, and we are evaluating the efficacy of many different compounds in a specific patient population. Again, this would be very difficult to conduct in a clinical setting with human subjects. These are things that synthetic in silico trials allow you to do that clinical endeavors would not." @CytoReason #DiseaseModels #ComputationalDiseaseModels #SyntheticClinicalTrials #ClinicalTrials #ComputationalBiology #DrugDevelopment #DrugDiscovery #AI #RareDiseases CytoReason.com Listen to the podcast here

Jeremy Skillington, CEO of Poolbeg Pharma #POLB discusses their deal with CytoReason, a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg's influenza disease progression data derived from human challenge study samples. The partnership will harness the insights of Poolbeg's unique repository of influenza human challenge trial* data and is another significant milestone in its strategy to leverage its proprietary databank to identify new pharmaceutical assets using artificial intelligence. CytoReason has built world-class validated AI models which can extrapolate immune cell behaviour based on bulk transcriptomics, making it an ideal partner to maximise the insights of Poolbeg's influenza data. To date, five of the world's top ten pharma companies use CytoReason's technology including Pfizer, Sanofi, Merck KGaA and Roche. Poolbeg's ability to execute a deal of this nature with a company of CytoReason's stature is a testament to the quality of Poolbeg's proprietary databank which will significantly improve the outputs of the collaboration. About Poolbeg Pharma Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire. The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.  With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections; a vaccine for Melioidosis, an oral vaccine delivery platform in development and two AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.

In this episode, Jonny heads to the Startup Nation to investigate a company who are making the impossible in medicine possible. Through artificial intelligence and machine learning, CytoReason are working with Big Pharma to find new targets to fight disease and improve drug development. They produce huge amounts of data, building disease models with it, so drawing parallels between what seemed unrelated diseases which doctors weren't able to see before. This is a remarkable story which offers human advancement to the world. #JonnyWalks is proudly sponsored by BOOST&Co.

Here's the mini-cast, part 2 of each month's record of Jonny's travels through the corridors of SMEs who are disrupting the big players and innovating with new processes and products. We return to "Furniture Central" in London's Tottenham Court Road for a shorter version of Jonny's interview with Keiran Hewkin, Lombok's Commercial Director, who with his partner, Paul Fielden have deconstructed then reconstructed "the way we think about buying furniture". Scroll back for the full interview with Keiran, Episode 3. It's really good! Then it's off to the Startup Nation, Israel, for an introduction to CytoReason, who use AI and Machine Learning to improve the efficacy of drugs. Their data will lead to better use of medication in patients and even cures for diseases. The full Episode 4 on CytoReason will follow in early March - but for a sneak preview we talk in this episode to Nurit Reder, who says after establishing themselves with no external investment - yes, they are entirely self-financing after just three years in business - they need to speed up Research and Development with a first round of fundraising. If they don't, someone will take their place at the top of computational biology. #JonnyWalks is proudly sponsored by BOOST&Co.

Professor Shai Shen-Orr and David Harel of Cytoreason talk about what they will miss ten years from now including a great comment about silence.

Professor Shai Shen-Orr and David Harel of Cytoreason talk about the future of precision medicine. The idea of being able to go to your personal doctor and asking how your immune system is doing seems like science fiction, but is likely to be a reality soon. Hear from two leading experts using AI and cell-based research to reveal the future of medicine.

On this episode, I speak with Shai Shen-Orr, cofounder and chief scientist of CytoReason ( www.cytoreason.com ). CytoReason has created a machine learning model of the immune system. This model can integrate data from multiple sources to support drug discovery, the creation of diagnostic tools, and more. In this episode, you’ll learn about systems immunology, its potential in medicine, and how CytoReason applies artificial intelligence to make sense of the growing body of immune-related data. This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or several other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .